Skip to main content

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

3D render of blood cells on abstract background © Image by kjpargeter on Freepik

The overarching aim of the group is to develop and trial new treatments for platelet disorders and finding alternatives to platelet transfusion.

  1. This includes trials of reversing antiplatelet drugs in intracerebral haemorrhage
  2. Optimising treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT)
  3. Clinical trials in transfusion medicine and immunohaematology [thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenia (ITP), warm autoimmune haemolytic anaemia (wAIHA), cold agglutinin disease (CAD)]
  4. Developing the evidence base for platelet transfusion and alternatives to transfusion

Our team

Collaborators

  • Professor Nikola Sprigg (University of Nottingham)
  • Dr Beth Psaila
  • Dr Lise Estcourt 
  • Dr Sue Pavord (University of Oxford)
  • Professor Samira Lakhal-Littleton (University of Oxford)
  • Dr Alex Bye (University of Reading)
  • Susan Brunskill (Systemic Reviews Initiative, NHS Blood and Transplant)

Related research themes